English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Lexicon Pharmaceuticals Inc
Suletud
Sektor Tervishoid
1.6
Ülevaade
Aktsiahinna muutus
24h
Min
1.6
Max
1.61
Sissetulek | -51M |
|---|---|
Müük | 540K 702K |
Aktsiakasum | -0.2 |
Kasumimarginaal | -31,188.272 |
Töötajad | 285 |
EBITDA | -49M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +417.39 upside |
Turukapital | -1.2M 510M |
|---|---|
Eelmine avamishind | 1.6 |
Eelmine sulgemishind | 1.6 |
Tehniline skoor
By Trading Central
Kindlus
Very Strong Bearish Evidence
Lexicon Pharmaceuticals Inc Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Lexicon Pharmaceuticals Inc Prognoos
Hinnasiht
By TipRanks
417.39% tõus
12 kuu keskmine prognoos
Keskmine 8.33 USD 417.39%
Kõrge 10 USD
Madal 5 USD
Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
